US Patent

US11643397 — Prolyl hydroxylase inhibitors

Method of Use · Assigned to GlaxoSmithKline LLC · Expires 2027-06-22 · 1y remaining

Vulnerability score 83/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects certain pyrimidinetrione N-substituted glycine derivatives that are antagonists of HIF prolyl hydroxylases.

USPTO Abstract

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

Drugs covered by this patent

Jesduvroq (DAPRODUSTAT) · GSK

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3535`	—	Jesduvroq
`U-3535`	—	Jesduvroq
`U-3535`	—	Jesduvroq
`U-3535`	—	Jesduvroq
`U-3535`	—	Jesduvroq

Patent Metadata

Patent number: US11643397
Jurisdiction: US
Classification: Method of Use
Expires: 2027-06-22
Drug substance claim: Yes
Drug product claim: No
Assignee: GlaxoSmithKline LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.